Introduction
Despite promising developments in the preclinical arena, and various plans for phase I/II clinical trials, there are as yet no treatments for muscular dystrophies based on their underlying molecular pathology. However, evidence based guidelines for management in many areas are now available, although randomized controlled trials remain rare. Most progress has been with the more common childhood muscular dystrophies, but our improved understanding of the natural history of the different types of muscular dystrophy and the predictable nature of the complications of other types of muscular dystrophies mean that many of these guidelines can be broadly applied, allowing prophylaxis and proactive management.
So, although it remains true that we do not have fundamental treatments aimed at the underlying pathology for any type of muscular dystrophy, we can nonetheless prevent and/or treat many of the life threatening complications of these diseases and thereby influence life expectancy and quality of life. Muscular dystrophies are often multisystem disorders, and it is involvement of the respiratory and cardiac systems that is the major cause of mortality in these diseases. Therefore, proactive management may have an important influence on longevity, whereas measures to improve or maintain strength through physiotherapy, orthopaedic surgery and medication may have an additional impact on natural history and quality of life.
Diagnosis
Although not strictly speaking a treatment modality, it is becoming increasingly clear that proper treatment depends on precise diagnosis. Careful DNA and muscle biopsy analysis can lead to a precise diagnosis in the majority of cases and, in addition to the obvious utility of this information for genetic counselling purposes, it is now becoming clear that these different precise diagnoses may carry specific implications for management [1 ,2-4,5 ,6 -8 , 9,10 ,11 ,12 -14,15 ,16,17,18 ,19, 20 ,21,22,23 ,24 ,25,26,27 -31 ,32,33 ,34,35 ,36,37,38 , 39] (Table 1 ). The current trend toward therapeutics based on stop codon read through or exon skipping in Duchenne muscular dystrophy (DMD) means that an even more precise diagnosis may be essential for future treatment modalities, and must be addressed where possible in every case [40 ,41 ] .
Drug treatments in the muscular dystrophies
Three recent reviews concluded that the use of corticosteroids (typically prednisone/prednisolone and [11 ,12,13] 5. Discuss the prophylaxis and treatment of chest infections via immunization, augmented coughing and antibiotic treatment as indicated [11 , 12,13] 6. Offer cardiac surveillance and treatment according to agreed guidelines (see text); note that cardiac insufficiency may be asymptomatic until a late stage and is often out of proportion to skeletal muscle weakness in BMD [14, 15 ] 7. Carriers of DMD/BMD should be offered cardiac surveillance [14] Myotonic dystrophy type 1 (DM1). Due to expansion in 3 0 -untranslated region of the DMPK gene. Molecular diagnosis readily available [16] 1. Genetic counselling issues are paramount, especially for women of childbearing age who are at risk for having congenitally affected children 2. Excessive daytime sleepiness may be due to respiratory problems (exclude respiratory failure) or may respond to modafanil [17] 3. Exercise may be of benefit [18 ] 4. There is a high risk for arrhythmia and sudden death, and surveillance and low threshold for pacemaker insertion is indicated [14] 5. Swallowing difficulties are common and may respond to speech and language therapy input [19] 6. Gastrointestinal symptoms may be a prominent problem in this group [20 ] 7. Other multisytem manifestations of this condition for which surveillance and treatment is indicated include diabetes and cataracts 8. Many patients complain of pain [21] Emery-Dreifuss muscular dystrophy (EDMD; autosomal dominant due to lamin A/C mutations and X-linked due to absence of the protein emerin). X-linked EDMD can be diagnosed on muscle biopsy and confirmed on DNA analysis. Mutation analysis is necessary to confirm laminopathy as protein analysis is usually normal [22] 1. Establish the precise genetic diagnosis because this is crucial for g enetic counselling: autosomal dominant EDMD is more common than X-linked EDMD, with a high incidence of new mutations 2. Autosomal dominant EDMD may be associated with many other multisystem problems including lipodystrophy and peripheral neuropathy, and there can be variable manifestations in affected family members [23 ] 3. Both X-linked and autosomal dominant EDMD are associated with potentially fatal arrhythmias and surveillance and early intervention may be life saving [14] 4. Because of the later development of ventricular arrhythmias and cardiomyopathy, it may be indicated in autosomal dominant EDMD to use implantable defibrillators rather than atrial pacemakers [14, 24 ] 5. Rigidity of the spine can precipate respiratory failure 6. Physiotherapy and orthopaedic input to contracture management may aid continued mobility Limb-girdle muscular dystrophies (LGMDs; a very heterogeneous group). Diagnosis relies on combined muscle biopsy and DNA analysis [25] 1.
LGMD2A and LGMD2B are rarely associated with respiratory or cardiac impairment 2.
LGMD2A: physiotherapy and orthopaedic input to contracture management may aid mobility 3. Sarcoglycanopathies: management principles are similar to dystrophinopathy with the need for scoliosis management, respiratory and cardiac surveillance and management [26] 4. LGMD2I: cardiac and respiratory problems (especially diaphragmatic involvement causing early respiratory failure) are common [27 ,28 ] 5.
LGMD1B: cardiac involvement is invariable and implantable defibrillator may be required (see autosomal dominent EDMD, above). Respiratory impairment is also common and requires surveillance and treatment [24 ] (continued overleaf ) deflazacort) are useful in maintaining or improving strength, at least in the ambulant phase of DMD [6 -8 ]. There is evidence from randomized controlled trials of daily steroid treatment (prednisone/prednisolone 0.75 mg/kg per day or deflazacort 0.9 mg/kg per day) of at least an 18 month gain in strength and probably also function. Long-term follow up studies (nonrandomized) indicate that there may be a major gain in terms of years of independent ambulation, improvement in respiratory function, reduction in need for scoliosis surgery, and possibly improvement in cardiac function [42 ,43-45] . Many alternative regimens, based on the principle of applying a lower overall dose or providing steroid intermittently or on an alternate day basis, have been suggested, and the intermittent regimen was recently proven to be superior to placebo [46 ] , but long-term follow up data for large numbers of patients are not available. Side effects of the daily regimens include weight gain and growth suppression, altered behaviour and increased risk for osteoporosis and cataracts (especially with deflazacort, although these cataracts are typically asymptomatic) [6 -8 ].
The use of corticosteroids is now in the mainstream of treatment for DMD and will be the gold standard against which future treatments will need to be judged [7 ] . Therefore, there needs to be a clear emphasis toward the prevention and management of the mainly predictable complications that may arise with their use, as well as potentially further trials of the different regimens compared against each other. As part of an effort to standardize the management of complications of steroid use, guidelines on the management of osteoporosis in DMD (which is in itself usually present even without the use of steroids) have been published and recommend reducing the risk for problems by ensuring a good intake of calcium and vitamin D through diet and sunshine, with use of bisphosphonates restricted to treatment of vertebral fractures only [47 -49 ] .
Use of corticosteroids in other types of muscular dystrophy is not so well founded. Extrapolating from their use in DMD, steroids have anecdotally been found to be useful in sarcoglycanopathy and some more severe cases of Becker muscular dystrophy. They do not appear to confer a specific benefit in other forms of muscular dystrophy.
Trials of other drugs in various types of muscular dystrophies (creatine, albuterol) have not to date shown any consistent or convincing benefit [50,51 ,52,53] .
Physiotherapy and orthopaedic input
Little evidence exists for the kinds of physiotherapy management that are most likely to be of benefit in muscular dystrophies. Joint contractures may exist as a primary and early part of the disease manifestation [such as in Emery-Dreifuss muscular dystrophy (EDMD) and
Bethlem myopathy] [30 ] or they may develop as a complication of weakness. Passive stretching and the use of night splinting or serial casting is often of value [9] . Orthopaedic input may be helpful, especially for Achilles tendon contractures that limit mobility or prevent rehabilitation in knee-ankle-foot orthoses, although other authors question its benefit [54] . Most patients benefit anecdotally from general advice to remain active and develop some kind of exercise programme suitable to their condition, and a modest benefit of such a programme has been shown for facioscapulohumeral muscular dystrophy (FSHD) [33 ,34] and myotonic dystrophy [18 ] .
Nonmolecular treatment for muscular dystrophies Bushby and Straub 513 Type of muscular dystrophy Major issues for management Bethlem myopathy. Caused by mutations in the collagen VI genes. The diagnostic process may be complex [29 ] 1. Physiotherapy and orthopaedic management of contractures may be necessary to maintain mobility 2. Respiratory impairment may develop with prominent diaphragmatic involvement [30 ] Facioscapulohumeral muscular dystrophy (FSHD).
Associated with chromosome 4q35 deletions. Molecular diagnosis is available [31 ] 1. In severe childhood onset FSHD, physiotherapy and orthopaedic input may be indicated for lordosis/contracture management 2. In severe FSHD there may be respiratory impairment but this is less common in milder disease [32] 3. Foot drop is common in FSHD and may be managed well with appropriate orthoses 4. Exercise programmes may be helpful for patients with FSHD [33 ,34] 5. Scapular fixation is well established as a treatment for scapular winging [35 ,36] 6. Pain is common in FSHD and may be difficult to control The congenital muscular dystrophies (CMDs). Very heterogeneous group. Diagnosis relies on combined muscle biopsy and DNA analysis [37] 1. Monitoring and treating respiratory insufficiency is essential in all types of CMD [28 ,38 ] 2. Physiotherapy and orthopaedic input are necessary for the management of disabling contractures and scoliosis 3. Feeding difficulties in CMD leading to undernutrition are common and may respond to tube or gastrostomy feeding [39] Physiotherapy may also play an important role in pain management (see below) [21, 22 ] .
Scoliosis is a major complication of DMD and some of the congenital muscular dystrophies. Scoliosis surgery, provided that it is carried out by an experienced team as part of a multidisciplinary approach to management with appropriate cover for potential cardiac and respiratory complications, may be a very successful treatment modality [10 ] .
For patients with prominent scapular winging, scapular fixation offers a good way to regain function, reduce pain and improve appearance [35 ,36] . This is most commonly applied to patients with FSHD but it may also be important for other conditions in which scapular winging is a major problem to patients, including some of the limb-girdle muscular dystrophies (LGMDs), notably the sarcoglycanopathies and calpainopathy. A Cochrane review on scapular fixation in muscular dystrophy [36] confirmed that operative interventions appear to produce significant benefits, although these must be balanced against postoperative immobilization, need for physiotherapy and potential complications [35 ] . The surgery requires a high level of experience and multidisciplinary treatment to optimize the chances of a successful outcome.
Cardiac surveillance and treatment
Many muscular dystrophies have specific effects on the heart (Table 1 ) [14] . There is an important group of muscular dystrophies in which cardiomyopathy is a major cause of mortality, whereas for others the main risk is of rhythm disturbance. Guidelines have been developed to standardize practice in this area, with recommendations based on mainly limited studies in muscular dystrophies and more extensive studies in other disease groups based on early treatment in the presence of progressive abnormalities to improve long-term prognosis. The muscular dystrophies in which cardiomyopathy is a significant risk include DMD and Becker muscular dystrophy, and several of the LGMDs including the sarcoglycanopathies and LGMD2I [14,27 ,55] . It is important to note that cardiomyopathy may in the milder forms of muscular dystrophy be out of proportion to the skeletal muscle involvement, with a severe cardiomyopathy developing while skeletal muscle function is well preserved, and that in the more severe muscular dystrophies cardiac involvement may be asymptomatic until a very late stage because of the limited activity of these patients. Guidelines therefore recommend regular echocardiographic review and intervention with angiotensin converting enzyme inhibition with/without b-blockade in the presence of progressive abnormalities [14] . One randomized controlled trial in DMD [15 ] has suggested that early angiotensin converting enzyme inhibition has a long-term protective effect on cardiac function, but further trials are necessary to establish the optimal time to start medication and the optimal combination of medications. In laminopathy (including autosomal dominant EDMD and LGMD1B) cardiomyopathy is usually a late complication preceded by arrhythmia [24 ] .
Arrhythmias tend to be the major cardiac complication in laminopathy, XL-EDMD and myotonic dystrophy [14, 24 ] . Regular surveillance and early intervention with a pacemaker is indicated in the presence of progressive abnormalities. The rhythm disturbance associated with laminopathy is particularly aggressive and may be difficult to treat. Dysrhythmias are present in 92% of patients by the age of 30 years and heart failure in 64% of patients over the age of 50 years. Sudden death occurred in 46% of a recently reported series [24 ] . Ventricular arrhythmias were the probable cause of sudden death in patients treated with pacemakers, and so treatment with implantable defibrillators may be the treatment of choice in this specific patient group. Because of these particularly severe and invariable complications, and the complex set of disorders that may be associated with lamin A/C mutations, the diagnosis of laminopathy should be explored in any patient with an undiagnosed muscular dystrophy phenotype.
Respiratory management in muscular dystrophies
Respiratory insufficiency in muscular dystrophies is most commonly the result of respiratory muscle weakness. Testing forced vital capacity in supine and standing positions is a simple test of respiratory muscle strength and diaphragmatic function and should be part of the regular assessment of all patients with muscular dystrophy. Falling forced vital capacity is an indication of increasing respiratory insufficiency, which may lead to increased rates of chest infections or more insidious signs of respiratory failure such as weight loss, loss of appetite and energy, increased waking and general malaise. Simple guidelines apply to the prevention and treatment of increasing respiratory insufficiency through the prophylaxis and treatment of chest infections with immunization, cough augmentation techniques and prompt treatment with antibiotics [11 ,38 ] .
It is now well established through many long-term cohort studies that patients with DMD respond very well to long-term nocturnal ventilation with improved longevity and good quality of life [12, 13, 56 ] . This intervention has had a greater impact on longevity in this disease group than any other intervention, with an improvement in life expectancy of at least 10 years, especially when combined with other treatment modalities such as spinal surgery (M. Eagle, M. Gibson, personal communication, June 2005). The same principles apply to other types of muscular dystrophy in which respiratory insufficiency is common with increasing muscle weakness, for example severe Becker muscular dystrophy and the sarcoglycanopathies. In other types of muscular dystrophy such as Bethlem myopathy and LGMD2I, the respiratory insufficiency may exhibit a different time course, with development of diaphragmatic weakness demonstrable by a fall in supine compared with standing forced vital capacity while patients are still ambulant [27 ,30 ] . Among the congenital muscular dystrophies, the profound muscular dystrophy is often accompanied by respiratory failure during the first or second decade [28 ,38 ] , whereas for other muscular dystrophies in this group the development of respiratory failure may be accelerated by the development of spinal rigidity, and for some specific subtypes (e.g. rigid spine muscular dystrophy type 1 due to SEPN1 mutations) respiratory failure may supervene while children are still ambulant [38 ] . The rarity of these subtypes of muscular dystrophy renders clinical trials largely impractical; however, accumulated clinical experience is clear in showing that for all of these subgroups respiratory support at the time of development of sleep disordered breathing relieves symptoms and improves life expectancy [57] .
Pain
There are few available data related to pain in muscular dystrophies. Many patients with muscular dystrophy experience a broad spectrum of coexisting pain types with a large number of potential causes. Pain can be exercise related, temperature modulated and palpation induced. It can be caused by abnormal posture or gait, joint instability or ligament sprain due to severe weakness, muscle cramping, nerve impingement because of muscle atrophy or dystrophy, prolonged use of a manual wheelchair (e.g. overuse) or pressure areas. No clear pattern of pain description appears to differentiate pain associated with any muscular dystrophy from the others. Patients with Becker muscular dystrophy or some LGMD subtypes may first present with cramps and myalgias; this has been particularly reported in LGMD1C or caveolinopathy and LGMD2I, but can probably be present in any type of LGMD [58] [59] [60] . Back, followed by leg, shoulder and neck are overall the most common sites for pain [61 ] . Depending on the type of muscular dystrophy and the stage of disease progression, musculoskeletal pain can be the most disabling symptom for patients. The ideal approach to pain control begins with the identification and then the elimination or treatment of the underlying aetiological factors.
Two recent surveys [21, 61 ] have begun to address the nature and scope of pain in adults with neuromuscular disorders, although with a broad group of underlying diagnoses. Up to 73% of patients reported pain, with 27% being severe and 39% interfering with activities of daily living. Patients with myotonic dystrophy reported the highest level of pain. Only 36% of the patients contacting a health professional received some kind of pharmacological pain treatment [21] .
Proper treatment is important because pain has an impact on mobility, normal work (including housework), enjoyment of life and recreational activities, and therefore it has a very important influence on quality of life. The large spectrum of therapeutic approaches to pain includes physical therapy, a long list of analgesic drugs (most commonly nonsteroidal anti-inflammatory agents, used with limited success in most patients), gabapentin, carbamazepine, muscle relaxants, tricyclic antidepressants, acupuncture, magnets, biofeedback and relaxation training, counselling, hypnosis, massage, chiropractic care, nerve blocks and occupational therapy. None of these treatments provided effective long-term relief, but many treatments were moderately effective, including the use of muscle relaxants, acupuncture and hypnosis [61 ] . Of the treatments that provided the greatest relief (chiropractic care and nerve blocks), only chiropractic care continued to be used by most patients who had tried it, which suggests that the costs and/or risks of repeated nerve block procedures may not have been worth the benefits. The very highly rated relief provided by chiropractic care is intriguing and suggests a strong case for a controlled trial of this treatment. Carbamazepine and tricyclic antidepressants were better among patients with severe pain [61 ] . Physiotherapy may also be of significant benefit; it was used by 89% of the patients in one study, with significant effect on pain relief in two-thirds. Wheelchair dependent patients in particular need proper support for sitting and lying. If problems with posture are identified, then specific and practical suggestions can be made for better management [62] . For patients with pain due to severe scapular winging, as is frequently seen in FSHD, scapular fixation can be an effective form of treatment [35 , 36] .
These recent studies are an indication that there is still a great deal of improvement needed in the treatment of pain in persons with muscular dystrophy, and that both patients and health care professionals tend to give a low priority to pain management, with detrimental effects on quality of life.
Gastrointestinal symptoms
Symptoms potentially due to malfunction of smooth muscle have been reported in patients with muscular dystrophy for many years. However, for many of the muscular dystrophies the frequency of gastrointestinal symptoms has never been prospectively evaluated [20 ] . An exception is myotonic dystrophy, in which gastrointestinal problems may be the presenting complaint and among the most predominant symptoms of the disease. Awareness of the various gastrointestinal manifestations in myotonic dystrophy can facilitate effective treatment, which could potentially be life saving. Oropharyngeal function in myotonic dystrophy type 1 (DM1) can be facilitated by strict adherence to reflux precautions, dietary counselling, strategies to facilitate pharyngeal clearance and airway protection strategies when aspiration risk is elevated [19, 20 ] . Gastroparesis in DM1 can be treated with the prokinetic drugs metoclopramide and cisapride. Erythromycin, a motilin agonist, has also been used as a prokinetic drug but it seems to be more effective in reducing diarrhoea in DM1. Cholestyramine can be used to treat patients with diarrhoea due to bile acid malabsorption [20 ] .
A recent study conducted by Motlagh et al. [63 ] suggested that patients with several forms of muscular dystrophy, including LGMD, FSHD and oculopharyngeal muscular dystrophy, may be prone to nutrient deficiency due to mobility limitations or oropharyngeal weakness. This major issue has already been noted for patients with congenital muscular dystrophy [39] . On the other side of the coin, obesity may also complicate muscular dystrophies, where food intake outstrips the ability to exercise. These issues all highlight the importance of nutritional assessment and counselling in patients with muscular dystrophy.
Anaesthesia
Although anaesthesia itself is not a therapy, there are several issues that must be considered if patients with muscular dystrophy undergo general anaesthesia [1 ]. Proper anaesthetic management of patients with muscular dystrophy, in particular those with myotonic dystrophy, can be life saving and it is therefore important that the anaesthesia plan is tailored to the needs of the patient and surgery. Even patients with apparently normal preoperative cardiac workup may succumb to adverse perioperative cardiac events [2] .
Typically in DMD, adverse cardiac events are responsible for most perioperative morbidity, whereas respiratory complications occur during the postoperative period [3]. Postoperatively, many patients with muscular dystrophy are at increased risk for respiratory compromise. The incidence of prolonged postoperative ventilation (>36 h) is increased in patients who have a preoperative forced vital capacity of less than 40% predicted [59] . However, multidisciplinary assessment and management of patients in a specialized setting with even severe respiratory compromise requiring nocturnal ventilation need not necessarily be a contraindication to necessary surgery [38 ] . Specific care with the use of specific inhalation anaesthetics and neuromuscular blockers is also indicated [1 ].
Conclusion
The large number of papers on management of muscular dystrophies cited in this review period contrasts with the barren period of the preceding years. Muscular dystrophies are now conditions in which proactive management can be shown to improve quality of life and life expectancy. A clear theme is the need for multidisciplinary management of potential complications.
In the future there will be a need for additional systematic reviews of possible treatment modalities, as well as well designed clinical trials. These require close attention to trial design and outcome measures. In other areas with these rare disorders, it is important to emphasize that trials may be problematic.
More specific treatments for muscular dystrophies will be coming to trial in the near future. It is important to realize that many of these will not be curative but will need to be added into the armoury of treatments already available. It is therefore important to ensure that all patients have access to the current highest possible standards of care, so that they will also benefit to the maximum from future developments.
